Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced that its Board of Directors will convene on October 27, 2026. The primary agenda item is to consider and approve the unaudited financial results, both standalone and consolidated, for the quarter ended September 30, 2026. Additionally, the company has closed its trading window for designated persons from October 1, 2026, which will reopen 48 hours after the financial results are disseminated, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

OneSource Specialty Pharma Limited has announced the closure of its trading window for dealing in the company's shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from October 1, 2026, and will reopen 48 hours after the declaration of the company's financial results for the quarter ending September 30, 2026. The specific date for the Board Meeting to approve these results will be communicated later.

Onesource Specialty Pharma Ltd announced the appointment of M/s BSR & Co LLP as its Statutory Auditors. This appointment was confirmed by shareholders at the 19th Annual General Meeting held on September 23, 2026. BSR & Co LLP will serve for a term of five consecutive years, from the conclusion of the 19th AGM until the conclusion of the 24th AGM. The firm is a well-established Chartered Accountant entity with a significant presence across India and experience auditing listed companies, including those in the pharmaceutical sector.

Onesource Specialty Pharma Ltd has issued an addendum to the notice of its 19th Annual General Meeting (AGM), scheduled for September 23, 2026. This addendum forms an integral part of the original notice dated July 24, 2026. It provides additional disclosures related to Item No. 6 & 7 of the AGM notice, specifically concerning material related party transactions (RPTs) with Strides Pharma Science Limited and its wholly-owned subsidiary, Strides Pharma Inc., USA. The addendum confirms that the Audit Committee has reviewed the necessary certificates from the CEO/CFO as per RPT industry standards. The updated information is available on the company's website and the stock exchanges.

Onesource Specialty Pharma Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report, filed as per SEBI regulations, details the company's corporate identity, operations, employee data, and market presence. Key highlights include 100% turnover from pharmaceutical manufacturing, serving over 20 states nationally and exporting to more than 30 countries, with exports contributing 70.80% to total turnover. The company employs 1,200 permanent employees and 1,089 workers, with a focus on sustainability and compliance. SGS India Private Limited provided reasonable assurance for core indicators.

Onesource Specialty Pharma Ltd has announced its 19th Annual General Meeting (AGM), which will be held on Wednesday, September 23, 2026, at 17:00 hours IST. The meeting will be conducted through video conferencing and Other Audio-Visual Means (OAVM). The company has also made its Integrated Annual Report for the financial year 2025-26 and the Notice of the 19th AGM, including e-voting instructions, available on its website and is dispatching them to eligible members. The report details the company's performance, strategic priorities, financial capital, and ESG initiatives.

Onesource Specialty Pharma Ltd has announced its 19th Annual General Meeting (AGM), which will be held on Wednesday, September 23, 2026, at 17:00 hours IST. The meeting will be conducted through video conferencing and Other Audio-Visual Means (OAVM). The company has also made its Integrated Annual Report for the financial year 2025-26 and the Notice of the 19th AGM, including e-voting instructions, available on its website and is dispatching them to eligible members. The report details the company's performance, strategic priorities, financial capital, and ESG initiatives.

Onesource Specialty Pharma Ltd has announced its 19th Annual General Meeting (AGM), which will be the second AGM after its listing. The meeting is scheduled for September 23, 2026, at 5:00 PM IST and will be conducted entirely through Video Conferencing or other Audio Visual Means (OAVM). This follows SEBI regulations and the Companies Act, 2013. The company has also made available the Notice of the 19th AGM, including e-voting instructions, and the Integrated Annual Report for the financial year 2025-26 on its website and through email dispatch to eligible members. The annual report details the company's performance, strategic priorities, and financial statements for FY26.

Onesource Specialty Pharma Ltd has announced changes in its Senior Management Personnel (SMP). Preeti Kalra, Head of Human Resources, has been designated as an SMP, effective July 24, 2026. Concurrently, Ravi Kumar, Global Head – Injectables/ Head of Corporate Strategy, Portfolio & SPO, has resigned from his position, also effective July 24, 2026. The company has provided disclosures as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including Ravi Kumar's resignation letter.

OneSource Specialty Pharma Ltd announced strong Q1FY27 results with revenue surging 37% year-on-year to ₹4,490 million and EBITDA growing 39% year-on-year to ₹1,233 million. This robust performance was driven by the commercial launch of semaglutide in Canada and India, new MSA contracts, and customer wins. EBITDA margins expanded to 27.5%. The company reaffirmed its FY28 guidance of $400 million in organic revenue with a 40% EBITDA margin. The CEO highlighted the upcoming commercial operations of a second cartridge line in Q2 and the addition of a new global biosimilar customer, underscoring the company's integrated CDMO capabilities and capacity expansion.